Key Takeaways
- Export disruption hit Q4 hard: March 2026 exports were largely lost to Iran-related shipping and logistics chaos, driving a year-on-year revenue decline and compressing gross margins through both higher input costs and lower operating leverage.
- Pune IV facility is the FY27 growth engine: Revenue from the new plant rose from ₹1.2 crore in Q3 to ₹2.7 crore in Q4, with management targeting ₹60–65 crore for FY27 and a utilization ramp from 40% to 70% across the four quarters.
- Base business guided at ₹80–85 crore: Combined with the Pune target, this implies a consolidated revenue ambition of roughly ₹140–150 crore for FY27, though quarterly lumpiness is expected.
- Margins face a transitional squeeze: Raw material prices spiked abnormally in March on war-driven speculation, and the new Pune plant will carry higher initial costs; management expects both pressures to ease as input prices settle and utilization scales.
- What to watch next quarter: Whether the alternative export routes via Saudi Arabia and Turkey actually restore March-level shipment volumes, the pace of product approvals for the Pune plant, and any movement on the long-pending Prague nutraceutical majority stake.
Export Operations & Geopolitical Disruption
- The March shock: Shipping routes, container availability and the entire logistical chain across the Middle East were disrupted by US-Iran conflict, preventing the company from executing its normal March export push. The disruption began late February; January and most of February were normal.
- Alternative routes deployed: Goods are now being transported to Saudi Arabia and then to Turkey for distribution, with additional focus on Southeast Asia routes. Management expects the disruption to persist for one to three months before normalization, contingent on government negotiations.
- Government support: A portion of the extra logistics charges incurred will be reimbursed by the Government of India.
- Export recovery expected in Q1 FY27: Management stated the impact of the disruption is largely behind them and expects broader export revenue recovery in the April-June 2026 quarter.
- Geographic risk spread: Exports contribute 76% of total turnover, diversified across Latin America, MENA, CIS and Southeast Asia; CIS exposure is described as very small.
Pritesh Jain: "the March month for this quarter was highly affected due to the geopolitical tensions on account of war between US and Iran. So, the shipping routes, availability of the containers and the logistical chain was disrupted and hence we couldn't do major shipments, which we normally do every year in the month of March."
Pune IV Fluid Facility Ramp-Up
- Current trajectory: Revenue contribution grew from ₹1.2 crore in Q3 FY26 to ₹2.7 crore in Q4 FY26. Commercial production began in December 2025, making FY26 the first year of contribution.
- Product approval pipeline: Five products are currently approved; 18 are in the pipeline, with a chunk of approvals expected this month. Scale-up is tied directly to individual product additions and approvals over time.
- Utilization ramp plan: Management laid out a gradual quarterly progression: 40%, 45%, 60%, reaching 70% by Q4 FY27.
- FY27 revenue target: ₹60–65 crore annual revenue expected; management declined to commit to a quarterly run-rate, focusing instead on the annualized number. The plant is expected to break even in FY27.
- Margin trajectory: Initial quarters (Q1, Q2) will see lower EBITDA or margin strain because the plant is newer with higher expenses; as scale builds into Q3 and Q4, margins will improve. Full-year EBITDA target for the plant is 17–18%.
Base Business & Product Mix
- FY27 base business target: ₹80–85 crore, with injectables growing 10–12%, tablets 7–8%, and nutraceuticals 8–9%.
- Product mix shift underway: The injectable portfolio will remain steady and increasing, but the tablet and capsule portfolio is expected to grow substantially as dossiers filed in various countries convert to approvals. A few dossier acceptances came last year; more are expected this year.
- Pricing model is flexible: The company does not have long-term fixed-price contracts with buyers; pricing is open and adjusts based on international price revisions and rates, providing a natural hedge against input cost swings.
- Competitive moat: Management points to a 25-year track record in injectables with no quality issues, and customer relationships spanning more than 15 years.
Pritesh Jain: "We don't have a long-term contract with our buyers wherein we are stuck for the price fixation. So, our price part is open depending on the international price revisions and rates."
Margins & Input Costs
- Q4 margin pressure: Higher raw material and packing input costs during March, combined with lower operating leverage from lost export dispatches, compressed gross margins.
- Raw material spike is receding: Prices skyrocketed abnormally in March due to war and speculation but are now settling down. The company maintains almost two months of inventory.
- Alternative sourcing secured: Alternative sources for plastics and aluminum have been found from China and Taiwan.
- Structural margin drivers: Margins are structurally supported by close monitoring of input costs including APIs and packing material.
- External variables: Sustained elevated crude oil prices and unfavorable USD-INR movement can impact input costs; part of any increase can be passed on, but some portion may hit margins. These are viewed as largely transitional factors.
Balance Sheet & Working Capital
- Receivables improved sharply: Debtor days reduced from 90 to 65, with receivables improving from 17.3 last year to 11.5 this year. The increase from FY24 levels is attributed to turnover growth from around ₹54 crores.
- Forward guidance on debtors: Expected to settle in the 55–60 day range in coming periods.
- Creditor position: Expected to improve as free cash flow increases, enabling the company to capture higher discounts.
Nutraceutical Venture & Other Updates
- Prague JV status: Parent Sanjivani holds a 45% minority stake; sales do not reflect in the consolidated balance sheet. Negotiations for a majority stake have been ongoing for two years but are yet to conclude. Improved commercial traction is expected during FY27.
- IV business bottomline: The IV business achieved its EBITDA margin targets in FY26, but interest and depreciation weighed on the bottomline since it is a newly started business; this is expected to even out gradually.
Ashwani Khemka: "we are under negotiation from majority state but it is yet to happen. When it will be happen we will be announcing it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Export revenue recovery | Broader recovery expected; disruption impact largely behind | Q1 FY27 (Apr–Jun 2026) |
| Pune IV facility utilization | Ramp from 40% → 45% → 60% → 70% across four quarters | Q1–Q4 FY27 |
| Pune IV facility annual revenue | ₹60–65 crore | FY27 |
| Base business annual revenue | ₹80–85 crore | FY27 |
| IV business breakeven | Breakeven expected | FY27 |
| Pune IV facility full-year EBITDA margin | 17–18% | FY27 |
| Debtor days | 55–60 days | Coming periods |
| Product approvals for Pune plant | Chunk of 18 pipeline products expected | This month |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹13.21 cr |
| Standalone base business revenue | ₹10.51 cr |
| Consolidated EBITDA | ₹2.17 cr, margin 15.74% |
| Standalone EBITDA | ₹1.66 cr, margin 14.7% |
| Consolidated PAT | ₹0.55 cr, margin 3.97% |
| Standalone PAT | ₹0.94 cr |
| Injectable revenue | ₹4.67 cr, 44.43% of standalone revenue |
| Tablet revenue | ₹5.46 cr, 51.95% of standalone revenue |
| Export revenue | ₹8.96 cr, 85.26% of standalone revenue |
| Domestic revenue | ₹1.47 cr |
| Core markets share | 76.09% of standalone revenue (Latin America, Middle East, Africa, CIS) |
| Pune IV facility revenue | ₹2.7 cr, up from ₹1.2 cr in Q3 FY26 |
| FY27 base business target | ₹80–85 cr |
| FY27 Pune IV plant target | ₹60–65 cr |
| FY27 base business EBITDA margin target | 15.5% to 16.5% |
| FY27 IV business EBITDA margin target | 17% to 18% on annualized basis |
| Debtor days | 65–70 days, improved from 90 days in prior year |
| Middle East and Africa revenue contribution | 40% to 45% of topline |
| Pune IV facility annual capacity | 6 cr bottles |
| Pune IV facility Q3+Q4 volume | 0.2 cr bottles, contributing ~₹3.5 cr revenue |
| Pune IV facility product approvals | 5 approved, 18 in pipeline |
| Prague nutraceutical JV revenue | EUR 500,000 to EUR 600,000 last year |
| Sanjivani stake in Prague JV | 45% |
| Import contribution | Less than 1% of total turnover |